Sign In

Steve Kafka

Managing Partner at Section 32

Steve Kafka is a prominent figure in the biotechnology sector, currently serving as the Chief Executive Officer at DA32 Life Science Tech Acquisition Corp. and as a General Partner at Section 32, a venture capital firm. He previously held the position of Executive Chairman at Thrive Earlier Detection Corp. from April 2019 until January 2021, where he played a crucial role in advancing early cancer detection through innovative blood tests.1235

Education and Early Career

Kafka earned his PhD in Political Economy and Government from Harvard University in 1996 and holds a BA in Economics and Political Science from Stanford University, completed in 1991.234 His career spans over two decades, during which he has held various leadership roles in notable biotech companies. Before his tenure at Thrive, he was the President and Chief Operating Officer at Foundation Medicine, which was acquired by Roche in 2018.34

Contributions to Biotechnology

At Thrive Earlier Detection, Kafka co-led the development of CancerSEEK, a groundbreaking liquid biopsy test designed to detect multiple types of cancer at earlier stages. This initiative aimed to integrate early cancer screening into routine medical practice, significantly shifting the focus of oncology towards prevention rather than treatment of late-stage diseases.13

In addition to Thrive, Kafka has served as Executive Chairman at ArcherDX, which was acquired by Invitae in 2020. His extensive experience also includes positions at various other biotech firms, including Aileron Therapeutics and Millennium Pharmaceuticals, where he contributed to financial strategy and operational growth.235

Current Roles

As of now, Kafka continues to influence the biotech landscape through his leadership at DA32 Life Science Tech Acquisition Corp. and his involvement with multiple companies focused on innovative healthcare solutions, including Glympse Bio and Rome Therapeutics.23 His ongoing work emphasizes the integration of advanced technologies in diagnostics and personalized medicine.

Highlights

Jan 1 · exai.bio
Steve Kafka | Exai - Exai Bio
Nov 5 · businesswire.com
Section 32 Names Steven J. Kafka, Ph.D., as Managing Partner
May 30 · fiercebiotech.com
With $110M and Johns Hopkins tech, Thrive aims to make early ...
Jul 18 · marketscreener.com
Steven Kafka: Positions, Relations and Network - MarketScreener

Related Questions

What is Steve Kafka's role at DA32 Life Science Tech Acquisition Corp?
How did Steve Kafka's career evolve after leaving Thrive Earlier Detection Corp?
What are the key projects Steve Kafka has been involved in at Section 32 LLC?
Can you provide more details about the CancerSEEK test developed by Thrive Earlier Detection Corp?
What are the main goals of Thrive Earlier Detection Corp?
Steve Kafka
Steve Kafka, photo 1
Steve Kafka, photo 2
Add to my network

Location

Cambridge, Massachusetts, United States